Wockhardt Limited (WOCKPHARMA.BO)
- Previous Close
570.25 - Open
578.95 - Bid 572.05 x --
- Ask 582.80 x --
- Day's Range
567.00 - 594.00 - 52 Week Range
167.00 - 630.00 - Volume
30,320 - Avg. Volume
68,105 - Market Cap (intraday)
88.888B - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-34.77 - Earnings Date May 24, 2024 - May 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 17, 2016
- 1y Target Est
450.00
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company's biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recombinant human insulin; Wepox, an r-DNA erythropoietin; human insulin; and Biovac-B, a hepatitis B vaccine. Its pipeline also includes long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. It also provides contract manufacturing services. The company was founded in 1967 and is headquartered in Mumbai, India.
www.wockhardt.com2,740
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: WOCKPHARMA.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WOCKPHARMA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WOCKPHARMA.BO
Valuation Measures
Market Cap
88.89B
Enterprise Value
110.48B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.02
Price/Book (mrq)
2.84
Enterprise Value/Revenue
3.99
Enterprise Value/EBITDA
129.97
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.05%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
27.76B
Net Income Avi to Common (ttm)
-5.01B
Diluted EPS (ttm)
-34.77
Balance Sheet and Cash Flow
Total Cash (mrq)
1.15B
Total Debt/Equity (mrq)
66.26%
Levered Free Cash Flow (ttm)
--
Research Analysis: WOCKPHARMA.BO
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: WOCKPHARMA.BO
WOCKPHARMA.BO does not have Company Insights